Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Conditions
Non Small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, CPT-11, Pegfilgrastim, Conformal radiotherapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Non-Small Cell Lung Cancer
Interventions
Erlotinib, Bemcentinib
Drug
Lead sponsor
BerGenBio ASA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Tampa, Florida + 5 more
Conditions
Colorectal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
16
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
Conditions
Breast Cancer
Interventions
gefitinib, tamoxifen citrate, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
gefitinib
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
50
States / cities
Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 43 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Gefitinib
Drug
Lead sponsor
David M. Jackman, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Neoplasms, Squamous Cell
Interventions
Gefitinib (Iressa), cisplatin, radiotherapy
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Conditions
Lung Cancer
Interventions
Bexarotene, Iressa
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Stanford, California
Conditions
Neoplasms, Unknown Primary
Interventions
Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
31
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 28 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Gefitinib, MEDI4736
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Houston, Texas • Seattle, Washington
Conditions
Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
Interventions
Irinotecan (Camptosar), Gefitinib (Iressa)
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Non Small Cell Lung Carcinoma
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Torrance, California • Macon, Georgia • Minneapolis, Minnesota + 6 more
Conditions
Non Small Cell Lung Cancer
Interventions
New use of osimertinib, New use of erlotinib or gefitinib
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Gefitinib, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 32 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Nonresectable Adrenocortical Carcinoma
Interventions
Iressa (ZD1839)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Louisville, Kentucky • Boston, Massachusetts • Lebanon, New Hampshire + 1 more
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
Interventions
Topotecan, Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Solid Tumors
Interventions
Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Myelogenous Leukemia, Acute
Interventions
gefitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
trastuzumab, gefitinib, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
gefitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Colorectal Cancer
Interventions
gefitinib
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
Interventions
ZD1839 (Gefitinib)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
626
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 623 more
Conditions
Lung Cancer
Interventions
carboplatin, gefitinib, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
140
States / cities
Scottsdale, Arizona • Fort Collins, Colorado • Jacksonville, Florida + 88 more